Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.

CONCLUSIONS: Chronic HCV/HIV co-infected patients with genotype 1 and 6 in the community setting could benefit from DAAs in Taiwan. PMID: 30360951 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30360951?dopt=Abstract

Source: Journal of Microbiology, Immunology, and Infection - October 12, 2018 Category: Microbiology Authors: Chen CP, Cheng CY, Zou H, Cheng CH, Cheng SH, Chen CK, Chen CH, Bair MJ Tags: J Microbiol Immunol Infect Source Type: research